{"id":"https://openalex.org/W1984788151","doi":"https://doi.org/10.1517/14656566.2014.971013","title":"Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC","display_name":"Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC","publication_year":2014,"publication_date":"2014-11-10","ids":{"openalex":"https://openalex.org/W1984788151","doi":"https://doi.org/10.1517/14656566.2014.971013","mag":"1984788151","pmid":"https://pubmed.ncbi.nlm.nih.gov/25381900"},"language":"en","primary_location":{"id":"doi:10.1517/14656566.2014.971013","doi":"https://doi.org/10.1517/14656566.2014.971013","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14656566.2014.971013","pdf_url":null,"source":{"id":"https://openalex.org/S52020611","display_name":"Expert Opinion on Pharmacotherapy","issn_l":"1465-6566","issn":["1465-6566","1744-7666"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Pharmacotherapy","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063843417","display_name":"Ashwin Somasundaram","orcid":"https://orcid.org/0000-0003-3167-406X","observed_orcids":["https://orcid.org/0000-0003-3167-406X"]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aswin Somasundaram","raw_affiliation_strings":["Lung Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lung Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078629724","display_name":"Mark A. Socinski","orcid":"https://orcid.org/0000-0003-2915-9325","observed_orcids":["https://orcid.org/0000-0003-2915-9325","https://orcid.org/0000-0002-8213-0137"]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark A Socinski","raw_affiliation_strings":["Lung Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lung Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5043862738","display_name":"Timothy Francis Burns","orcid":"https://orcid.org/0000-0002-8685-3762","observed_orcids":["https://orcid.org/0000-0002-8685-3762"]},"institutions":[{"id":"https://openalex.org/I170201317","display_name":"University of Pittsburgh","ror":"https://ror.org/01an3r305","country_code":"US","type":"education","lineage":["https://openalex.org/I170201317"]},{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Timothy F Burns","raw_affiliation_strings":["Lung Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA; Assistant Professor of Medicine, University of Pittsburgh, Hillman Cancer Center Research Pavilion, Division of Hematology-Oncology, 5117 Centre Avenue, Suite 2.18e, Pittsburgh, PA 15213-1863, USAburnstf@upmc.edu","University of Pittsburgh, Pittsburgh, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lung Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA; Assistant Professor of Medicine, University of Pittsburgh, Hillman Cancer Center Research Pavilion, Division of Hematology-Oncology, 5117 Centre Avenue, Suite 2.18e, Pittsburgh, PA 15213-1863, USAburnstf@upmc.edu","institution_ids":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]},{"raw_affiliation_string":"University of Pittsburgh, Pittsburgh, United States","institution_ids":["https://openalex.org/I170201317"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.8551,"has_fulltext":false,"cited_by_count":23,"citation_normalized_percentile":{"value":0.6169501,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"15","issue":"18","first_page":"2693","last_page":"2708"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/egfr-mutation","display_name":"EGFR mutation","score":0.765999972820282},{"id":"https://openalex.org/keywords/alk-positive-lung-adenocarcinoma","display_name":"ALK-positive lung adenocarcinoma","score":0.8289999961853027},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9959999918937683},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9850000143051147},{"id":"https://openalex.org/keywords/egfr-tki-resistance","display_name":"EGFR tyrosine kinase inhibitor resistance","score":0.7300000190734863},{"id":"https://openalex.org/keywords/crizotinib","display_name":"crizotinib","score":0.9309999942779541},{"id":"https://openalex.org/keywords/ceritinib","display_name":"ceritinib","score":1.0},{"id":"https://openalex.org/keywords/third-generation-egfr-tki","display_name":"third-generation EGFR-TKI","score":0.8880000114440918},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.8619999885559082},{"id":"https://openalex.org/keywords/adjuvant-therapy","display_name":"adjuvant therapy","score":0.9620000123977661},{"id":"https://openalex.org/keywords/acquired-resistance","display_name":"acquired resistance","score":0.3919999897480011}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8834694623947144},{"id":"https://openalex.org/C2779422266","wikidata":"https://www.wikidata.org/wiki/Q5186964","display_name":"Crizotinib","level":4,"score":0.8752580881118774},{"id":"https://openalex.org/C117643217","wikidata":"https://www.wikidata.org/wiki/Q17824987","display_name":"Anaplastic lymphoma kinase","level":4,"score":0.843766450881958},{"id":"https://openalex.org/C2779750558","wikidata":"https://www.wikidata.org/wiki/Q21011233","display_name":"Ceritinib","level":5,"score":0.7985509634017944},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.544368326663971},{"id":"https://openalex.org/C2994294914","wikidata":"https://www.wikidata.org/wiki/Q1645075","display_name":"Acquired resistance","level":3,"score":0.5398314595222473},{"id":"https://openalex.org/C2780586478","wikidata":"https://www.wikidata.org/wiki/Q4688818","display_name":"Afatinib","level":5,"score":0.5396513938903809},{"id":"https://openalex.org/C2777626846","wikidata":"https://www.wikidata.org/wiki/Q21506464","display_name":"Osimertinib","level":5,"score":0.521854043006897},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.5134959816932678},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4979720115661621},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.496232807636261},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.4864661395549774},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.4167305827140808},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.41057324409484863},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.3884313404560089},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.36816009879112244},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.1703498363494873},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.08823040127754211},{"id":"https://openalex.org/C2776232967","wikidata":"https://www.wikidata.org/wiki/Q6743514","display_name":"Malignant pleural effusion","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000077547","descriptor_name":"Crizotinib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077548","descriptor_name":"Anaplastic Lymphoma Kinase","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020794","descriptor_name":"Receptor Protein-Tyrosine Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D057285","descriptor_name":"Precision Medicine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1517/14656566.2014.971013","doi":"https://doi.org/10.1517/14656566.2014.971013","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14656566.2014.971013","pdf_url":null,"source":{"id":"https://openalex.org/S52020611","display_name":"Expert Opinion on Pharmacotherapy","issn_l":"1465-6566","issn":["1465-6566","1744-7666"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Pharmacotherapy","raw_type":"journal-article"},{"id":"pmid:25381900","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25381900","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on pharmacotherapy","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9779000282287598,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":118,"referenced_works":["https://openalex.org/W1514134885","https://openalex.org/W1860735374","https://openalex.org/W1931438814","https://openalex.org/W1967394241","https://openalex.org/W1969018910","https://openalex.org/W1970299210","https://openalex.org/W1973323865","https://openalex.org/W1974903221","https://openalex.org/W1975165936","https://openalex.org/W1978236936","https://openalex.org/W1980497534","https://openalex.org/W1990687470","https://openalex.org/W1996666174","https://openalex.org/W1997476230","https://openalex.org/W1998322093","https://openalex.org/W2005216767","https://openalex.org/W2016278956","https://openalex.org/W2016692297","https://openalex.org/W2017757358","https://openalex.org/W2019539885","https://openalex.org/W2031494655","https://openalex.org/W2037632369","https://openalex.org/W2038586807","https://openalex.org/W2040878803","https://openalex.org/W2043696829","https://openalex.org/W2044247525","https://openalex.org/W2052294822","https://openalex.org/W2055402151","https://openalex.org/W2056780782","https://openalex.org/W2061278019","https://openalex.org/W2065141010","https://openalex.org/W2065477010","https://openalex.org/W2065947397","https://openalex.org/W2066417528","https://openalex.org/W2078484622","https://openalex.org/W2080992857","https://openalex.org/W2081801534","https://openalex.org/W2088669044","https://openalex.org/W2096156234","https://openalex.org/W2096198395","https://openalex.org/W2100541925","https://openalex.org/W2102625113","https://openalex.org/W2103225497","https://openalex.org/W2104830962","https://openalex.org/W2106915761","https://openalex.org/W2109080255","https://openalex.org/W2111361612","https://openalex.org/W2111662961","https://openalex.org/W2112474794","https://openalex.org/W2113327188","https://openalex.org/W2114032749","https://openalex.org/W2115527176","https://openalex.org/W2120718661","https://openalex.org/W2123138079","https://openalex.org/W2123727052","https://openalex.org/W2126298634","https://openalex.org/W2128208856","https://openalex.org/W2129360604","https://openalex.org/W2132157071","https://openalex.org/W2133963438","https://openalex.org/W2134607826","https://openalex.org/W2134787029","https://openalex.org/W2135192471","https://openalex.org/W2136245016","https://openalex.org/W2138515877","https://openalex.org/W2139110945","https://openalex.org/W2139236349","https://openalex.org/W2140333474","https://openalex.org/W2143859186","https://openalex.org/W2144126883","https://openalex.org/W2145980885","https://openalex.org/W2146404049","https://openalex.org/W2150371178","https://openalex.org/W2151016309","https://openalex.org/W2153477391","https://openalex.org/W2154149901","https://openalex.org/W2154905832","https://openalex.org/W2158638287","https://openalex.org/W2160982674","https://openalex.org/W2161817637","https://openalex.org/W2161821474","https://openalex.org/W2162394887","https://openalex.org/W2162724777","https://openalex.org/W2164943366","https://openalex.org/W2166084034","https://openalex.org/W2168691181","https://openalex.org/W2169816570","https://openalex.org/W2170144893","https://openalex.org/W2170568643","https://openalex.org/W2171139285","https://openalex.org/W2174680146","https://openalex.org/W2185481272","https://openalex.org/W2240169541","https://openalex.org/W2245637869","https://openalex.org/W2257265893","https://openalex.org/W2264514575","https://openalex.org/W2297901492","https://openalex.org/W2419498329","https://openalex.org/W2461360472","https://openalex.org/W2462237620","https://openalex.org/W2470636097","https://openalex.org/W2480872124","https://openalex.org/W2520220492","https://openalex.org/W2527444926","https://openalex.org/W2559651048","https://openalex.org/W2566863750","https://openalex.org/W2589957652","https://openalex.org/W2595746152","https://openalex.org/W2596364503","https://openalex.org/W2599403941","https://openalex.org/W2599973369","https://openalex.org/W2604731859","https://openalex.org/W2605292800","https://openalex.org/W2626223149","https://openalex.org/W2997762406","https://openalex.org/W2998884390","https://openalex.org/W2999214779","https://openalex.org/W2999792303"],"related_works":["https://openalex.org/W2773891005","https://openalex.org/W2360967040","https://openalex.org/W3113189792","https://openalex.org/W1600335608","https://openalex.org/W2004327117","https://openalex.org/W1965615508","https://openalex.org/W1570854499","https://openalex.org/W1744290301","https://openalex.org/W2162903802","https://openalex.org/W1559511540"],"abstract_inverted_index":{"INTRODUCTION:":[0],"The":[1],"epidermal":[2],"growth":[3],"factor":[4],"receptor":[5],"(EGFR)":[6],"is":[7,23,152,164,178],"mutated":[8],"in":[9,25,40,48,103,117,126,140,146,156,171],"15%":[10],"of":[11,13,27,29,33,94,121],"adenocarcinomas":[12,28],"the":[14,18,30,72,78,88,104,118,147,157,172],"lung.":[15,31],"In":[16],"addition,":[17],"anaplastic":[19],"lymphoma":[20],"kinase":[21,44],"(ALK)":[22],"altered":[24],"8%":[26],"Treatment":[32,113],"EGFR":[34,98,115,122,135],"mutant":[35,99,123],"and":[36,53,82,91,100,108,143,166],"ALK":[37],"translocation-positive":[38],"tumors":[39],"NSCLC":[41,102,124,170],"with":[42,114],"tyrosine":[43],"inhibitors":[45],"(TKI)":[46],"results":[47,125],"a":[49,127],"dramatic":[50],"therapeutic":[51,92],"response":[52],"has":[54],"revolutionized":[55],"therapy.":[56],"Unfortunately,":[57],"resistance":[58,149,174,187],"to":[59,70,86,154,180,184,188],"TKIs":[60,116,136],"invariably":[61],"develops.":[62],"Many":[63],"promising":[64,132],"new":[65],"therapies":[66,183],"are":[67,137],"under":[68],"investigation":[69,177],"overcome":[71,185],"resistance.":[73],"AREAS":[74],"COVERED:":[75],"We":[76],"analyzed":[77],"current":[79],"primary":[80],"literature":[81],"recent":[83],"national":[84],"meetings":[85],"evaluate":[87],"clinical":[89,129],"characteristics":[90],"implications":[93],"relevant":[95],"treatments":[96],"for":[97,160,168],"ALK-positive":[101,161,169],"first-line,":[105],"acquired":[106,148,173,186],"resistance,":[107],"adjuvant":[109],"settings.":[110],"EXPERT":[111],"OPINION:":[112],"first-line":[119,158],"setting":[120,159],"significant":[128],"benefit.":[130],"Several":[131],"third":[133],"generation":[134],"being":[138],"evaluated":[139],"Phase":[141],"II":[142],"III":[144],"trials":[145],"setting.":[150,175],"Crizotinib":[151],"superior":[153],"chemotherapy":[155],"NSCLC.":[162],"Ceritinib":[163],"effective":[165],"approved":[167],"Continued":[176],"needed":[179],"develop":[181],"novel":[182],"TKIs.":[189]},"counts_by_year":[{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2019,"cited_by_count":4},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":5}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}